Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
This article was originally published in The Gray Sheet
Boston Scientific and Cyberonics report disappointing data on vagus nerve stimulation to treat heart failure at the European Society of Cardiology conference in Barcelona. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
You may also be interested in...
The yet-to-be-named combined company is predicting big opportunities, particularly, heart failure, sleep apnea and cardiac surgery.
Edwards Lifesciences gains corporate VP from Medtronic. Cyberonics exec resigns. More people briefs.
European Approval For BioControl Medical’s Nerve Stimulation System For Treatment-Resistant Depression
BioControl Medical’s FitNeS vagus nerve stimulation system now has a second approved European indication: treatment-resistant depression. This follows the implantable neuromodulation system’s first CE mark for drug-resistant epilepsy in 2010.